Prostate Cancer Clinical Trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging

Summary

This phase III trial compares the addition of apalutamide, with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT), may help doctors look for cancer that has spread to the pelvis. Androgens can cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET/CT results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. For patients without PET-evidence of extrapelvic metastases, to evaluate whether the addition of enhanced systemic therapy to standard of care (SOC) salvage radiation therapy (RT) could prolong progression-free survival (PFS).

II. For patients with PET-evidence of extrapelvic metastases, to evaluate whether the addition of metastasis-directed RT to enhanced systemic therapy and SOC salvage RT could prolong PFS.

SECONDARY OBJECTIVES:

I. To evaluate overall survival (OS) in each arm. II. To evaluate event-free survival (EFS) in each arm. III. To evaluate time to prostate-specific antigen (PSA) progression using Prostate Cancer Working Group (PCWG) 2 criteria in each arm.

IV. To assess the incidence of adverse events with the addition of enhanced systemic therapy in patients without PET-evidence of extrapelvic metastases.

V. To assess the incidence of adverse events with local ablative metastasis-directed RT for PET-positive metastatic disease in patients with PET-evidence of extrapelvic metastases.

VI. To estimate the detection rate of PET/CT at the patient and regional level, and to evaluate its concordance with the follow-up Food and Drug Administration (FDA)-approved conventional imaging modalities (CIM) considered standard-of-care per institution, including CT, bone scintigraphy, magnetic resonance imaging (MRI) and PET imaging performed as PET/CT and/or PET/MR using 11C-choline and/or 18F-sodium fluoride.

VII. To determine the distribution of PET-positive lesions among anatomic sites (prostate fossa, intrapelvic soft tissue/lymph node, extrapelvic soft tissue/lymph node, and bone metastases) in patients with post-radical prostatectomy (RP) biochemical recurrence (BCR), correlated with PSA (level, doubling time, velocity) and other relevant clinical parameters.

VIII. To determine the value of repeat PET at 12 months (PET2) to assess response to therapy (enhanced systemic therapy +/- focal RT and/or androgen deprivation therapy [ADT]) compared to standard response assessments (PSA and CIM).

OUTLINE:

STEP 0: Patients receive fluciclovine F18 intravenously (IV) and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arms C or D below undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.

STEP 1: Patients are randomized to 1 of 4 arms based on results of fluciclovine F18 PET/CT in Step 0.

ARM A (PET NEGATIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC external beam radiation therapy (EBRT) for 6 months. Patients also receive goserelin acetate subcutaneously (SC) or leuprolide acetate intramuscularly (IM) for 6 months starting up to 3 months prior to EBRT but no later than the first fraction of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.

ARM B (PET NEGATIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide orally (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity.

ARM C: (PET POSITIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD as in Arm B.

ARM D (PET POSITIVE FOR EXTRA PELVIC-METASTASES): Patients undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo stereotactic body radiation therapy (SBRT) or 3-dimensional (3D) conformal radiation therapy (CRT), intensity-modulated radiation therapy (IMRT) (including volume modulated arc therapy [VMAT]), and intensity-modulated proton therapy (IMPT) over 3-5 fractions in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for years 1-3 and then every 6 months for years 4-5.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

STEP 0: REGISTRATION ELIGIBILITY CRITERIA
Patient must have had a radical prostatectomy (RP) as definitive therapy for histopathologically-proven prostatic adenocarcinoma

Patient must have biochemical recurrence (BCR) after RP, with rising PSA defined as follows:

If time to biochemical recurrence, (defined as time to first detectable PSA after RP) is < 12 months, a minimum PSA level of >= 0.2 ng/mL and a confirmatory reading of >= 0.2 ng/mL is required, per the American Urological Association (AUA) definition (this includes patients with a persistent PSA reading of at least 0.2 ng/mL)

If time to biochemical recurrence, (defined as time to first detectable PSA after RP) is >= 12 months, a minimum absolute PSA of 0.5 ng/mL is required

NOTE: Qualifying PSA values per above must be collected at least 4 weeks after RP, with confirmatory persistent or elevated PSA collected at any subsequent time point
Patient must be negative or equivocal for extrapelvic metastatic disease by conventional imaging modalities (CIM) (i.e., bone scans, pelvic CT, or pelvic MRI), which must be done within 10-12 weeks prior to registration. Extra-pelvic metastases is defined as any osseous metastases and/or any extrapelvic soft tissue, lymph nodes and organ metastases; extra-pelvic is defined as superior to common iliac bifurcation, outside of standard prostate bed + whole pelvis nodal RT fields
Baseline PET/CT scan (PET1) are eligible for this study if the SOC PET scan using 18F-fluciclovine (Axumin) is completed during step 0 registration or up to 12 weeks prior to step 0 registration. The PET/CT scanners must meet scanner qualifications and scans must have an interpretation (or confirmation of an institutional clinical read) by a nuclear medicine physician or radiologist who has undergone 18F-fluciclovine (Axumin) reader training
Patient must be a candidate for standard-of-care (SOC) post-prostatectomy radiation therapy (RT) to the prostate bed and pelvic nodes with androgen deprivation therapy (adjuvant)
Patient must have the ability to provide written informed consent
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Patient must be able to lie flat and still for approximately 20-30 minutes or otherwise tolerate a PET/CT scan and radiation treatment planning and delivery
Patient must be at a participating institution, which has agreed to perform the imaging research studies, completed the ECOG-American College of Radiology Imaging Network (ACRIN) defined PET/CT scanner qualification procedures and received ECOG-ACRIN PET/CT scanner approval
Leukocytes >= 3,000/mcL (obtained within 4 weeks prior to registration)
Absolute neutrophil count >= 1,500/mcL (obtained within 4 weeks prior to registration)
Platelets >= 100,000/mcL (obtained within 4 weeks prior to registration)
Total bilirubin =< institutional upper limit of normal (ULN) (obtained within 4 weeks prior to registration)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained within 4 weeks prior to registration)
Glomerular filtration rate (GFR) > 35 mL/min estimated by Cockcroft-Gault or measured directly by 24 hour urine creatinine (obtained within 4 weeks prior to registration)
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class I or II (by patient symptoms) or A or B (by objective assessment)
STEP 1: RANDOMIZATION ELIGIBILITY CRITERIA
Patient must have completed a baseline SOC PET scan (PET1) with results of extra-pelvic metastases involvement known (positive or negative)
For patients with negative extra-pelvic metastases, PET-imaging status of intra-pelvic nodes must be known (positive or negative)
For patients with positive extra-pelvic metastases (defined as any PET positive lesions outside of standard salvage RT fields [prostate bed +/- typical whole pelvis]), the number of extra-pelvic lesions must be known (=< 5 or > 5 pelvic lesions)

Exclusion Criteria:

Patient must not have started androgen deprivation therapy for biochemical recurrence prior to baseline study PET/CT imaging
Patient must not be enrolled in another therapeutic clinical trial
Patient must not have any other malignancy within the last 2 years, other than superficial bladder cancer and skin basal cell carcinoma or cutaneous superficial squamous cell carcinoma that has not metastasized
Patient must not have history of seizures or known condition that may cause predisposal to seizures (e.g., stroke or head trauma resulting in loss of consciousness) within 1 year of registration
Patient must not have history of inflammatory bowel disease as this would increase risk of complication from radiotherapy or any gastrointestinal disorder affecting absorption
Patient must not have had prior radiation therapy

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

804

Study ID:

NCT04423211

Recruitment Status:

Recruiting

Sponsor:

ECOG-ACRIN Cancer Research Group

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 81 Locations for this study

See Locations Near You

City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States More Info
Scott M. Glaser
Contact
626-218-2247
[email protected]
Scott M. Glaser
Principal Investigator
UC San Diego Moores Cancer Center
La Jolla California, 92093, United States More Info
Site Public Contact
Contact
858-822-5354
[email protected]
James M. Randall
Principal Investigator
Los Angeles County-USC Medical Center
Los Angeles California, 90033, United States
USC / Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States
Sibley Memorial Hospital
Washington District of Columbia, 20016, United States More Info
Site Public Contact
Contact
202-243-2373
[email protected]
Curtiland Deville
Principal Investigator
Saint Alphonsus Cancer Care Center-Boise
Boise Idaho, 83706, United States More Info
Site Public Contact
Contact
734-712-3671
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell Idaho, 83605, United States More Info
Site Public Contact
Contact
734-712-3671
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Alphonsus Cancer Care Center-Nampa
Nampa Idaho, 83687, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Luke's Cancer Institute - Twin Falls
Twin Falls Idaho, 83301, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Alison K. Conlin
Principal Investigator
Northwestern University
Chicago Illinois, 60611, United States More Info
Site Public Contact
Contact
312-695-1301
[email protected]
Sean Sachdev
Principal Investigator
Carle on Vermilion
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Sinisa Stanic
Principal Investigator
Northwestern Medicine Cancer Center Kishwaukee
DeKalb Illinois, 60115, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
William F. Hartsell
Principal Investigator
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Sinisa Stanic
Principal Investigator
Northwestern Medicine Cancer Center Delnor
Geneva Illinois, 60134, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
William F. Hartsell
Principal Investigator
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Sinisa Stanic
Principal Investigator
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Sinisa Stanic
Principal Investigator
The Carle Foundation Hospital
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Sinisa Stanic
Principal Investigator
Northwestern Medicine Cancer Center Warrenville
Warrenville Illinois, 60555, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
William F. Hartsell
Principal Investigator
Jewish Hospital
Louisville Kentucky, 40202, United States
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
Biddeford Maine, 04005, United States More Info
Site Public Contact
Contact
[email protected]
Matthew D. Cheney
Principal Investigator
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
Sanford Maine, 04073, United States More Info
Site Public Contact
Contact
[email protected]
Matthew D. Cheney
Principal Investigator
Maine Medical Center- Scarborough Campus
Scarborough Maine, 04074, United States More Info
Site Public Contact
Contact
207-396-8090
[email protected]
Matthew D. Cheney
Principal Investigator
Maine Medical Partners - South Portland
South Portland Maine, 04106, United States More Info
Site Public Contact
Contact
207-396-8670
[email protected]
Matthew D. Cheney
Principal Investigator
University of Maryland/Greenebaum Cancer Center
Baltimore Maryland, 21201, United States More Info
Site Public Contact
Contact
800-888-8823
Mark V. Mishra
Principal Investigator
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore Maryland, 21287, United States More Info
Site Public Contact
Contact
410-955-8804
[email protected]
Curtiland Deville
Principal Investigator
Suburban Hospital
Bethesda Maryland, 20814, United States More Info
Site Public Contact
Contact
301-896-2719
[email protected]
Curtiland Deville
Principal Investigator
University of Mississippi Medical Center
Jackson Mississippi, 39216, United States More Info
Site Public Contact
Contact
601-815-6700
John C. Henegan
Principal Investigator
Siteman Cancer Center at West County Hospital
Creve Coeur Missouri, 63141, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Jeff M. Michalski
Principal Investigator
Washington University School of Medicine
Saint Louis Missouri, 63110, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Jeff M. Michalski
Principal Investigator
Siteman Cancer Center-South County
Saint Louis Missouri, 63129, United States More Info
Jeff M. Michalski
Principal Investigator
Siteman Cancer Center at Christian Hospital
Saint Louis Missouri, 63136, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Jeff M. Michalski
Principal Investigator
Siteman Cancer Center at Saint Peters Hospital
Saint Peters Missouri, 63376, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Jeff M. Michalski
Principal Investigator
CoxHealth South Hospital
Springfield Missouri, 65807, United States More Info
Site Public Contact
Contact
417-269-4520
Jay W. Carlson
Principal Investigator
Cooper Hospital University Medical Center
Camden New Jersey, 08103, United States More Info
Site Public Contact
Contact
856-325-6757
Gary Eastwick
Principal Investigator
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States More Info
Site Public Contact
Contact
732-235-7356
Tina Mayer
Principal Investigator
Community Medical Center
Toms River New Jersey, 08755, United States More Info
Site Public Contact
Contact
732-557-8294
[email protected]
Tina Mayer
Principal Investigator
MD Anderson Cancer Center at Cooper-Voorhees
Voorhees New Jersey, 08043, United States More Info
Site Public Contact
Contact
856-325-6757
Gary Eastwick
Principal Investigator
Montefiore Medical Center-Einstein Campus
Bronx New York, 10461, United States More Info
Site Public Contact
Contact
718-379-6866
[email protected]
Benjamin A. Gartrell
Principal Investigator
Mount Sinai Chelsea
New York New York, 10011, United States More Info
Site Public Contact
Contact
212-824-7309
[email protected]
Bobby Liaw
Principal Investigator
Mount Sinai Hospital
New York New York, 10029, United States More Info
Site Public Contact
Contact
212-824-7309
[email protected]
Bobby Liaw
Principal Investigator
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati Ohio, 45219, United States
Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Site Public Contact
Contact
800-293-5066
[email protected]
Shang-Jui Wang
Principal Investigator
University of Cincinnati Cancer Center-West Chester
West Chester Ohio, 45069, United States
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Tyler Gunter
Principal Investigator
Legacy Mount Hood Medical Center
Gresham Oregon, 97030, United States
Legacy Good Samaritan Hospital and Medical Center
Portland Oregon, 97210, United States
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Site Public Contact
Contact
503-494-1080
[email protected]
Arthur Y. Hung
Principal Investigator
Legacy Meridian Park Hospital
Tualatin Oregon, 97062, United States
Fox Chase Cancer Center - East Norriton Hospital Outpatient Center
East Norriton Pennsylvania, 19401, United States More Info
Site Public Contact
Contact
[email protected]
Mark A. Hallman
Principal Investigator
UPMC Hillman Cancer Center Erie
Erie Pennsylvania, 16505, United States More Info
Site Public Contact
Contact
412-389-5208
[email protected]
Adam Olson
Principal Investigator
Fox Chase Cancer Center Buckingham
Furlong Pennsylvania, 18925, United States More Info
Site Public Contact
Contact
215-794-2700
Mark A. Hallman
Principal Investigator
Penn State Milton S Hershey Medical Center
Hershey Pennsylvania, 17033, United States More Info
Site Public Contact
Contact
717-531-3779
[email protected]
Joseph A. Miccio
Principal Investigator
Penn Presbyterian Medical Center
Philadelphia Pennsylvania, 19104, United States More Info
Site Public Contact
Contact
[email protected]
Neha Vapiwala
Principal Investigator
University of Pennsylvania/Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States More Info
Site Public Contact
Contact
800-474-9892
Neha Vapiwala
Principal Investigator
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States More Info
Site Public Contact
Contact
215-728-4790
Mark A. Hallman
Principal Investigator
Temple University Hospital
Philadelphia Pennsylvania, 19140, United States More Info
Site Public Contact
Contact
215-728-2983
Mark A. Hallman
Principal Investigator
UPMC-Magee Womens Hospital
Pittsburgh Pennsylvania, 15213, United States More Info
Site Public Contact
Contact
412-647-2811
Adam Olson
Principal Investigator
UPMC-Saint Margaret
Pittsburgh Pennsylvania, 15215, United States More Info
Site Public Contact
Contact
412-784-4900
Adam Olson
Principal Investigator
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh Pennsylvania, 15232, United States More Info
Site Public Contact
Contact
412-647-8073
Adam Olson
Principal Investigator
UPMC-Shadyside Hospital
Pittsburgh Pennsylvania, 15232, United States More Info
Site Public Contact
Contact
412-621-2334
Adam Olson
Principal Investigator
UPMC-Saint Clair Hospital Cancer Center
Pittsburgh Pennsylvania, 15243, United States More Info
Site Public Contact
Contact
412-502-3920
Adam Olson
Principal Investigator
UPMC Washington Hospital Radiation Oncology
Washington Pennsylvania, 15301, United States More Info
Site Public Contact
Contact
724-223-3788
[email protected]
Adam Olson
Principal Investigator
UPMC Susquehanna
Williamsport Pennsylvania, 17701, United States More Info
Site Public Contact
Contact
800-598-4282
Adam Olson
Principal Investigator
Medical University of South Carolina
Charleston South Carolina, 29425, United States More Info
Site Public Contact
Contact
843-792-9321
[email protected]
Harriet B. Eldredge-Hindy
Principal Investigator
UT Southwestern/Simmons Cancer Center-Dallas
Dallas Texas, 75390, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Kevin D. Courtney
Principal Investigator
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth Texas, 76104, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Kevin D. Courtney
Principal Investigator
UT Southwestern Clinical Center at Richardson/Plano
Richardson Texas, 75080, United States More Info
Site Public Contact
Contact
972-669-7044
[email protected]
Kevin D. Courtney
Principal Investigator
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States More Info
Site Public Contact
Contact
210-450-3800
[email protected]
Michael A. Liss
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
Alfredo I. Urdaneta
Principal Investigator
FHCC South Lake Union
Seattle Washington, 98109, United States More Info
Site Public Contact
Contact
800-804-8824
Jonathan J. Chen
Principal Investigator
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States More Info
Site Public Contact
Contact
800-804-8824
Jonathan J. Chen
Principal Investigator
University of Washington Medical Center - Montlake
Seattle Washington, 98195, United States More Info
Site Public Contact
Contact
800-804-8824
Jonathan J. Chen
Principal Investigator
Legacy Cancer Institute Medical Oncology and Day Treatment
Vancouver Washington, 98684, United States
Legacy Salmon Creek Hospital
Vancouver Washington, 98686, United States
Langlade Hospital and Cancer Center
Antigo Wisconsin, 54409, United States More Info
Site Public Contact
Contact
715-623-9869
[email protected]
Andrew J. Huang
Principal Investigator
Marshfield Medical Center-EC Cancer Center
Eau Claire Wisconsin, 54701, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Isaac K. Yeboah
Principal Investigator
UW Cancer Center Johnson Creek
Johnson Creek Wisconsin, 53038, United States More Info
Site Public Contact
Contact
920-699-3500
[email protected]
John M. Floberg
Principal Investigator
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Site Public Contact
Contact
800-622-8922
John M. Floberg
Principal Investigator
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Isaac K. Yeboah
Principal Investigator
Marshfield Clinic-Minocqua Center
Minocqua Wisconsin, 54548, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Isaac K. Yeboah
Principal Investigator
Marshfield Medical Center-Rice Lake
Rice Lake Wisconsin, 54868, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Isaac K. Yeboah
Principal Investigator
Ascension Saint Michael's Hospital
Stevens Point Wisconsin, 54481, United States More Info
Site Public Contact
Contact
715-847-2353
[email protected]
Andrew J. Huang
Principal Investigator
Marshfield Medical Center-River Region at Stevens Point
Stevens Point Wisconsin, 54482, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Isaac K. Yeboah
Principal Investigator
Aspirus Regional Cancer Center
Wausau Wisconsin, 54401, United States More Info
Site Public Contact
Contact
877-405-6866
Andrew J. Huang
Principal Investigator
Marshfield Medical Center - Weston
Weston Wisconsin, 54476, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Isaac K. Yeboah
Principal Investigator
Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids Wisconsin, 54494, United States More Info
Site Public Contact
Contact
715-422-7718
Andrew J. Huang
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

804

Study ID:

NCT04423211

Recruitment Status:

Recruiting

Sponsor:


ECOG-ACRIN Cancer Research Group

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.